EGFR and non-small cell lung carcinoma: A recognized general notion is that TKI-treated NSCLC patients with complex EGFR-mutations (≥2 different co-existing EGFR-mutations) show inferior RR and shorter PFS than patients with single EGFR-mutations, unless the combined mutations are the common exon19dels and L858R [55,56].